DWTX Dogwood enrolls first 200 patients in ongoing halneuron® phase 2B chemotherapy induced neuropathy trial; top-line data expected in fall

DWTX Dogwood enrolls first 200 patients in ongoing halneuron® phase 2B chemotherapy induced neuropathy trial; top-line data expected in fall 2026